Business Context and Reporting Period
This Form 8-K filing by AngioDynamics, Inc. (NASDAQ: ANGO) reports a material change in executive leadership. The report date is October 16, 2019, with the effective date of the changes set for October 23, 2019.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on personnel changes.
Material Changes
- Departure of CFO: Michael C. Greiner will cease serving as Executive Vice President and Chief Financial Officer effective October 23, 2019.
- Transition Period: Mr. Greiner agreed to remain with the company through the filing of the Form 10-Q for the second fiscal quarter ending November 30, 2019.
- Interim Appointment: Stephen A. Trowbridge, Senior Vice President and General Counsel, was named interim Chief Financial Officer effective October 23, 2019.
- Search for Permanent CFO: The company has initiated a process to identify a permanent Chief Financial Officer.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, outlook, or specific risk factors related to the leadership change. It notes that Mr. Trowbridge's appointment involves no changes to his compensation package and that he has no material interest in transactions requiring disclosure under Item 404(a) of Regulation S-K. A press release regarding these events was issued on October 22, 2019.
Investor Verification Checklist
- Verify the timeline for the search and appointment of a permanent Chief Financial Officer.
- Review the upcoming Form 10-Q for the quarter ended November 30, 2019, for any financial commentary from the interim CFO.
- Monitor for any subsequent press releases regarding the permanent CFO selection.